>
产品中心 >
Protein_purification_kit >
ACROBiosystems/ActiveMax® Human IL-7 Protein, Tag Free/20ug/IL7
- SynonymIL7,Interleukin-7
- SourceActiveMax® Human IL-7, Tag Free (IL7-H4219) is expressed from human 293 cells (HEK293). It contains AA Asp 26 - His 177 (Accession # P13232).Predicted N-terminus: Asp 26Request for sequence
- Molecular Characterization
This protein carries no "tag".
The protein has a calculated MW of 17.4 kDa. The protein migrates as 24 kDa and 25-28 kDa under reducing (R) condition (SDS-PAGE) due to different glycosylation.
- EndotoxinLess than 1.0 EU per μg by the LAL method.
- Purity
>95% as determined by SDS-PAGE.
- Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
- Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
- Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
ActiveMax® Human IL-7, Tag Free on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Immobilized ActiveMax® Human IL-7, Tag Free (Cat. No. IL7-H4219) at 2 μg/mL (100 μL/well) can bind Human IL-7 R alpha, Fc Tag (Cat. No. ILA-H5258) with a linear range of 1-16 ng/mL (QC tested).
Captured Human IL-7 R alpha, Fc Tag (Cat. No. ILA-H5258) on CM5 chip via anti-human IgG Fc antibodies surface can bind ActiveMax® Human IL-7, Tag Free (Cat. No. IL7-H4219) with an affinity constant of 23.9 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Captured Human IL-7 R alpha, Mouse IgG2a Fc Tag (Cat. No. IL7-H5258) on CM5 chip via anti-mouse antibodies surface can bind ActiveMax® Human IL-7, Tag Free (Cat. No. IL7-H4219) with an affinity constant of 13.3 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
ActiveMax®HumanIL-7, Tag Free(Cat. No. IL7-H4219)stimulates proliferationof PHA-P-activatedhuman peripheralblood mononuclearcell (PBMC).TheED50for this effect is 0.108-0.829 ng/mL (Routinely tested).
- BackgroundInterleukin 7 is also known as IL7, IL-7, and is a hematopoietic growth factor secreted by stromal cells in the red marrow and thymus. It is also produced by keratinocytes, dendritic cells, hepatocytes, neurons, and epithelial cells, but is not produced by lymphocytes. IL-7 stimulates the differentiation of multipotent (pluripotent) hematopoietic stem cells into lymphoid progenitor cells, It also stimulates proliferation of all cells in the lymphoid lineage (B cells, T cells and NK cells). It is important for proliferation during certain stages of B-cell maturation, T and NK cell survival, development and homeostasis. IL-7 is a cytokine important for B and T cell development. This cytokine and the hepatocyte growth factor (HGF) form a heterodimer that functions as a pre-pro-B cell growth-stimulating factor. IL-7 binds to the IL-7 receptor, a heterodimer consisting of Interleukin-7 receptor alpha and common gamma chain receptor. Il-7 promotes hematological malignacies (acute lymphoblastic leukemia, T cell lymphoma). Elevated levels of IL-7 have also been detected in the plasma of HIV-infected patients. IL-7 as an immunotherapy agent has been examined in many pre-clinical animal studies and more recently in human clinical trials for various malignancies and during HIV infection. IL-7 could also be beneficial in improving immune recovery after allogenic stem cell transplant.
- References
(1)Heufler C, et al. 1993, J. Exp. Med. 178 (3): 1109–14.
(2)Kröncke R, et al. 1996, Eur. J. Immunol. 26 (10): 2541–4.
(3)Sawa Y, et al. 2009, Immunity 30 (3): 447–57.
(4)Muegge K, et al. 1993, Science 261 (5117): 93–5.
(5)Noguchi M, et al. 1994, Science 262 (5141): 1877–80.
(6)Snyder KM,et al. 2006, Leuk. Lymphoma 47 (7): 1222–8.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
